Por: New York Daily News Nation February 25, 2023
The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus (RSV) vaccine. Two people in their 60s who received the shot were diagnosed with Guillain-Barre syndrome, out of about 20,000 vaccine recipients who participated in Pfizer’s Phase 3 clinical trial, according to the FDA document. One person’s illness had completely resolved after... + full article
ABC7 USA Health March 02, 2023
vaccines for adults over the age of 60. The vaccine candidates, made by Pfizer and GlaxoSmithKline, could become the world's first approved vaccines against the common virus.The video featured is from a previous report.On Wednesday, committee members voted 10-2 in support... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
ABC News USA Business March 01, 2023
WASHINGTON -- Federal advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.The Food and Drug Administration panel voted 7-4 on two separate questions of... + más
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year | CNN
1st RSV vaccine could be approved this summer | ABC7
CNBC USA Health March 01, 2023
Blood sample for respiratory syncytial virus (RSV) testJarun011 Istock Getty ImagesThe Food and Drug Administration's independent advisors on Tuesday recommended what would be the world's first RSV vaccine, a shot from for adults ages 60 and older, despite safety... + más
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults | CNBC
FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccine | New York Daily News
Associated Press USA Health March 01, 2023
WASHINGTON (AP) — Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.The Food and Drug Administration panel voted 7-4 on two separate... + más
WPLG Local 10 USA Health March 01, 2023
WASHINGTON – Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.The Food and Drug Administration panel voted 7-4 on two separate... + más
watch nowVIDEO1:5501:55FDA advisory panel votes in favor of adult RSV vaccine from GSK PLCThe Food and Drug Administration's independent panel of advisors on Wednesday recommended RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over... + más
FDA Panel Backs GSK’s RSV Vaccine for Older People | Time
GSK vaccine for older adults granted FDA priority review | Fox Business
CNBC USA Health February 24, 2023
In this articleThis 1981 photo provided by the Centers for Disease Control and Prevention (CDC) shows an electron micrograph of Respiratory Syncytial Virus, also known as RSV.CDC via APThe Food and Drug Administration sees a possible risk of Guillain-Barre syndrome with 's... + más
FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks | CNBC
RSV vaccine: FDA advisers vote in favor of approval for vaccines for older adults | ABC7
About iurex | Privacy Policy | Disclaimer |